Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial

Hepatology Research

Volumn 41, Issue 6, 2011, Pages 505-511

  Matsuura, Kentaro ^a   Tanaka, Yasuhito ^a   Kusakabe, Atsunori ^a   Hige, Shuhei ^d   Inoue, Jun ^e   Komatsu, Masashi ^f   Kuramitsu, Tomoyuki ^g   Hirano, Katsuharu ^h   Ohno, Tomoyoshi ^b   Hasegawa, Izumi ^b   Kobashi, Haruhiko ⁱ   Hino, Keisuke ^j   Hiasa, Yoichi ^k   Nomura, Hideyuki ^l   Sugauchi, Fuminaka ^c   Nojiri, Shunsuke ^a   Joh, Takashi ^a   Mizokami, Masashi ^m  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b CHUKYO HOSPITAL   (Japan)

^c Koseiin Medical Welfare Center   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f AKITA CITY HOSPITAL   (Japan)

^g Kuramitsu Clinic   (Japan)

^h JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

ⁱ OKAYAMA UNIVERSITY   (Japan)

^j KAWASAKI MEDICAL SCHOOL   (Japan)

^k EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l Shin Kokura Hospital   (Japan)

^m NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

more..

Author keywords

Chronic hepatitis B; Entecavir; Lamivudine; Lamivudine resistance; Randomized controlled trial; Switching treatment

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ADD ON THERAPY; ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; MALE; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEROLOGY; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS HEPATITIS;

EID: 79957551116     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00807.x     Document Type: Article

References (30)

1. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
2. Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 2006; 11: 669-79.
3. Di Marco V, Marzano A, Lampertico P etal. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 883-91.
4. Papatheodoridis GV, Dimou E, Dimakopoulos K etal. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121-9.
5. Lai CL, Chien RN, Leung NW etal. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
6. Dienstag JL, Schiff ER, Wright TL etal. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 21 (341): 1256-63.
7. Lai CL, Dienstag J, Schiff E etal. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
8. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
9. Lok AS, Lai CL, Leung N etal. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
10. Chang TT, Lai CL, Chien RN etal. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 1276-82.
11. Kobayashi M, Suzuki F, Akuta N etal. Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment. Hepatol Res 2010; 40: 125-34.
12. Allen MI, Deslauriers M, Andrews CW etal. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-7.
13. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-72.
14. Westland CE, Yang H, Delaney W etal. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepat 2005; 12: 67-73.
15. Chang TT, Gish RG, de Man R etal. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
16. Lai CL, Shouval D, Lok AS etal. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
17. Sherman M, Yurdaydin C, Sollano J etal. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-49.
18. Colonno RJ, Rose R, Baldick CJ etal. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44: 1656-65.
19. Tenney DJ, Rose RE, Baldick CJ etal. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5years of therapy. Hepatology 2009; 49: 1503-14.
20. Sherman M, Yurdaydin C, Simsek H etal. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96weeks. Hepatology 2008; 48: 99-108.
21. Tenney DJ, Pokornowski K, Rose RE etal. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2008; 2: S302-3.
22. Kumada H, Okanoue T, Onji M etal. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010; 40: 1-7.
23. Liaw YF, Leung N, Kao JH etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
24. European Association for the Study of the Liver.EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
25. Reijnders JG, Deterding K, Petersen J etal. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010; 52: 493-500.
26. Suzuki Y, Suzuki F, Kawamura Y etal. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3years: histological improvement or entecavir resistance? J Gastroenterol Hepatol 2009; 24: 429-35.
27. Mukaide M, Tanaka Y, Shin IT etal. Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation. Antimicrob Agents Chemother 2010; 54: 882-9.
28. Kim HJ, Park JH, Park DI etal. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol 2010; 25: 1374-80.
29. Suzuki F, Akuta N, Suzuki Y etal. Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients. J Gastroenterol Hepatol 2010; 25: 892-8.
30. Kurashige N, Ohkawa K, Hiramatsu N etal. Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance. J Gastroenterol 2009; 44: 864-70.